Share tips of the week
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
Three to buy
GlaxoSmithKline
(Shares) GSK’s shares are on a deep discount compared to peer AstraZeneca. They yield 6.5% but analysts think dividend cover next year will be tight. Yet the market is missing key strengths: a robust vaccine division – notably thanks to its Shingrix vaccine – and a “strong pipeline” at the oncology franchise. The consumer healthcare joint venture with Pfizer will also unlock cost savings and better margins. On a price/earnings ratio (p/e) of 11 the stock is appealing. Buy. 1,221p
Hiscox
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(The Mail on Sunday) “Should you buy an insurer in the middle of a global catastrophe?” Hiscox is a diversified player, offering everything from “big ticket insurance” of oil rigs to niche retail policies for art and kidnap cover. With Covid-19 striking so broadly this has been a “torrid” year, but recent trading updates suggest the ship is steadying and premium income has kept growing. With the stock down by half since July 2019 Hiscox could prove “a good policy”. 942p
Kingfisher
(Investors Chronicle) Lockdown is no problem for the B&Q and Screwfix-owner, which operates in the UK, France, Poland and Romania. Classified as “essential”, the stores are likely to see a sales surge as housebound Europeans look for something to keep themselves occupied. New management is de-centralising operations to make managers more responsive to local conditions and more people are getting the DIY bug. On 15 times 2022 earnings this is a reasonably-priced turnaround play. Buy. 287p
Three to sell
Dropbox Inc.
(Forbes.com) This cloud-storage specialist reported more than 15 million paying users in the third quarter. Yet its ability to take market share from larger rivals remains in question. The group is struggling to distinguish itself from Google, Apple and Microsoft, which offer more services and are frequently more competitive on price. The shares are priced for implausibly rapid growth. The current valuation implies 46 million paying users by 2027, or 30% of Amazon Prime’s US membership. Given the rich valuation, the risks are tilted to the downside, so avoid. $19
Mercantile Investment Trust
(The Times) This FTSE-250 Trust offers concentrated exposure to the UK market through quality holdings such as Computacenter and Games Workshop. The portfolio is focused on the industrial, financial and consumer sectors but avoids oil and gas. British stocks are trading near 50-year lows and some money managers sense long-term opportunity. Perhaps, but with a double-dip recession looming the FTSE still faces significant headwinds, so all but “the fearless” should avoid. 199p
Ryanair
(The Sunday Telegraph) Ryanair’s latest update showed sales down 78% and a near-€200m after-tax loss over the six months through September. Impressive cost savings and €4.5bn of cash mean that “it will survive” and there will be fewer competitors on the other side of the pandemic. Yet survival is no guarantee of returns, especially with the shares only 14% below their pre-pandemic level. Stick to shares that are less likely to face continued turbulence. €13.34
...and the rest
The Daily Telegraph
Gresham House Strategic Trust has been hoovering up deeply discounted UK micro-cap shares. Patient, risk-tolerant investors could be rewarded when the market turns. Buy (985p). British software “gem” Blancco helps companies delete old data to comply with data-protection laws. It is a leader in this niche and the longer-term growth opportunity is very promising – buy (191p).
Investors Chronicle
US-based Thermo Fisher Scientific is a leading provider of scientific laboratory kit. Business has received a fillip during the coronavirus, while the group should also enjoy a long-term tailwind from rising healthcare spending. Buy ($481).
The Mail on Sunday
Self-storage is a rare bright spot amid the gloom for commercial landlords. Lok’nStore may also gain from the house-buying boom as people need storage space between moves. Hold (565p).
Shares
Newly listed Canadian gold play Wheaton Precious Metals is a “streaming” company – meaning it invests in mining without directly assuming operational risks. There are few comparable businesses on the London market and it offers a new way to buy into the ongoing strength of the yellow metal (3,725p). Microsoft continues to beat analysts’ forecasts thanks to the work-from-home boom, justifying its central role in many a portfolio.Keep buying ($202).
The Times
Packaging firm DS Smith is exposed to the e-commerce boom and on just nine times forecast earnings the shares “look wildly undervalued”.Buy (290p).
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published
-
Should investors stay bullish and buy UK and US stocks?
Opinion Ignore the Eeyores, says Max King. The outlook for stocks in both Britain and America remains auspicious
By Max King Published